Noven To Present at Deutsche Bank Small Cap Growth Conference

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that Robert C. Strauss, its President, CEO & Chairman, is scheduled to provide an update on Noven’s business and prospects at the Deutsche Bank Small Cap Growth Conference in Naples, Florida on Tuesday, February 13, 2007, at 12:00 noon Eastern Time. The public is invited to listen to the presentation live via webcast at www.noven.com, and a replay will be available for at least two weeks at the same site.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven’s prescription patches are approved in over 30 countries and include Vivelle-Dot™ (the most prescribed estrogen patch in the U.S.) and Daytrana™ (the first and only patch approved for the treatment of ADHD). A range of new patches is under development by Noven in collaboration with industry partners. Noven is committed to expanding the universe of available transdermal therapies for the benefit of patients, partners and shareholders. See www.noven.com for additional information.

Contact:
Alina Bowman
Investor Relations Coordinator
305-253-1916